TARGET-BASED METHOD FOR HIGH-THROUGHPUT AND SUBCLASS SPECIFIC IgG GLYCAN PROFILING IN HUMAN PLASMA
US-2024353417-A1 · Oct 24, 2024 · US
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US10167332B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10167332-B2 |
| Application number | US-29488307-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2007 |
| Priority date | Apr 5, 2006 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
First claim
Opening claim text (preview).
What is claimed is: 1. A modified IVIG composition prepared from an unmodified IVIG composition, wherein the modified IVIG composition has (i) increased anti-inflammatory activity as compared to the unmodified IVIG composition, and (ii) a higher content of α2,6 linked sialic acid in the N-linked glycans of Fc regions than the unmodified IVIG composition. 2. The modified IVIG composition of claim 1 wherein the modified IVIG composition has a higher a higher content of α2,6 linked N-acetylneuraminic acid in the N-linked glycans of Fc regions than the unmodified IVIG composition. 3. A pharmaceutical composition comprising the modified IVIG composition of claim 1 and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition comprising the modified IVIG composition of claim 2 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Immunoglobulins · CPC title
Glycopeptides, glycoproteins · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10167332B2 cover?
- The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
- Who is the assignee on this patent?
- Ravetch Jeffrey V, Kaneko Yoshikatsu, Falk Nimmerjahn, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).